0RGI.LSE COSMO Pharmaceuticals SA

Healthcare Commercial Services & Supplies London Exchange
87.98 GBP
Close of Nov 3, 2026
49.20 129.57
Market cap
GBP 1.32B
P/E
42.4x
P/B
-
ROE
-3.3%
Dividend yield
0.03%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0RGI.LSE undervalued?

Graham number

The Graham number of COSMO Pharmaceuticals SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

COSMO Pharmaceuticals SA fundamental analysis

No fundamental analysis for COSMO Pharmaceuticals SA yet.

COSMO Pharmaceuticals SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About COSMO Pharmaceuticals SA

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to…

Full company profile